VGX Pharmaceuticals announces publication in *Molecular Therapy* regarding the Company's GHRH gene therapy product

Blue Bell, PA - May 22, 2008 -

VGX Pharmaceuticals Inc. (VGX) and its affiliate, VGX Animal Health Inc. (VGXAH), announced today the publication in *Molecular Therapy*, the official journal of the American Society for Gene Therapy (http://www.nature.com/mt/index.html), of their work related to the Company's leading Growth Hormone Releasing Hormone (GHRH) gene therapy product for the treatment of cancer-related anemia in companion dogs with spontaneous malignancies (Bodles-Brakhop et al., Double-blinded, Placebo-controlled Plasmid GHRH Trial for Cancer-associated Anemia in Dogs, *Molecular Therapy*, 2008, 16:862-870).

Cachexia and its associated disorders affect up to 5 million people in the United States alone and represent common complications of cancer, aging, acquired immunodeficiency syndrome, chronic kidney or heart failure. Prevalent cancer-associated conditions such as fatigue and poor quality of life may be induced by the cancer itself or by cancer treatments such as chemotherapy, with anemia being one of its leading causes in patients. Similar conditions and symptoms are shared by humans and animals alike.

In the published study, VGX researchers tested the use of a non-viral DNA molecule, called a plasmid, which encodes for growth hormone-releasing hormone (GHRH) in 55 companion dogs with spontaneous malignancies and anemia receiving a cancer-specific treatment in a double-blinded, placebo-controlled trial. Dogs received a single, low dose of plasmid or placebo, delivered intramuscularly by the Company's CELLECTRA® constant current electroporation device. Plasmid-treated dogs had increases in all red blood cell count, hemoglobin and hematocrit. Post-hoc analysis of the GHRH-treated group showed that responder dogs survived significantly longer than non-responders and controls. In addition, quality of life, as defined by 10 different parameters, improved dramatically with treatment including increases in appetite and decreases in complications of cancer-related therapies, such as diarrhea and vomiting.

"Publication of this study stresses the potential of VGX technology to improve human and animal health," stated Dr. J. Joseph Kim, President and Chief Executive Officer. "We are optimistic that our novel GHRH programs will significantly expand the treatment options for cancer patients."

VGX Pharmaceuticals is waiting for approval from the Food and Drug Administration to study the GHRH treatment (VGX-3200) in humans. VGX Animal Health also plans to develop this product for companion dogs and cats.

Cautionary Factors That May Affect Future Results - Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, PENNVAX™-B for HIV infection, which is in 2 separate Phase I clinical trials, and VGX-1027 for inflammatory diseases, which is in Phase I clinical trials. In addition, the Company has filed INDs for VGX-3100, a DNA therapeutic vaccine for cervical cancer; VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia; and VGX-3400, a DNA preventative vaccine for avian influenza. VGX has established a vertically-integrated DNA Vaccines and Therapies Platform with extensive capabilities including SynCon™ DNA-based product candidates, the CELLECTRA® delivery device, and efficient cGMP plasmid manufacturing facilities. The cGMP facilities are used for VGX's own product supplies and for contract manufacturing. Vertical control over key aspects of product development has enabled the Company to consistently develop multiple product candidates, from bench-to-IND filing, within 1 year. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

About VGX Animal Health

VGX Animal Health, Inc. ("VGXAH" or "The Company") was formed in 2007 as a majority-owned subsidiary of VGX Pharmaceuticals, Inc. (VGXP) specializing in animal health therapeutics. VGXAH's products and technology were initially developed by ADViSYS Inc, which was founded in 1997 and acquired by VGX Pharmaceuticals in early 2007. VGXAH's lead product, LifeTide™ SW 5, was approved in Australia in January 2008. The product is an injectable plasmid encoding for porcine Growth Hormone Release Hormone ("GHRH"). In addition, the Company has conducted

extensive pre-clinical trials for other applications of its proprietary plasmid-based GHRH therapy in both food and companion animals. Treatment of cancer cachexia, anemia, and improved milk production are just a few of the many potential applications of this technology in animal health. VGXAH's product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGXAH can be found at www.vgxah.com.

Company Contact:

Kevin W. Rassas
Senior Vice-President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com